Skip to content
10-Q

Quarterly Report

PharmaCyte Biotech, Inc. PMCB

0001683168-24-008709

← back to feed
Filed
Dec 13, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Dec 9, 2024 6.97M sh
Cash And Equivalents Q2 2025 · Oct 31, 2024 $20.84M
Cash And Equivalents Q2 2025 · Apr 30, 2024 $50.18M
Current Liabilities Q2 2025 · Oct 31, 2024 $4.78M
Current Liabilities Q2 2025 · Apr 30, 2024 $7.42M
Total Liabilities Q2 2025 · Oct 31, 2024 $11.65M
Total Liabilities Q2 2025 · Apr 30, 2024 $20.39M
Current Assets Q2 2025 · Oct 31, 2024 $21.33M
Current Assets Q2 2025 · Apr 30, 2024 $50.44M
Total Assets Q2 2025 · Oct 31, 2024 $55.1M
Total Assets Q2 2025 · Apr 30, 2024 $59.9M
Shares Diluted Q2 2025 · Oct 31, 2023 8.77M sh
Shares Diluted Q2 2025 · Oct 31, 2023 10.68M sh
Stock Repurchased Q2 2025 · Oct 31, 2023 $26.62M
Operating Cash Flow Q2 2025 · Oct 31, 2023 −$1.64M
Stockholders Equity Q2 2025 · Oct 31, 2023 $36.77M
Stockholders Equity Q2 2025 · Jul 31, 2023 $39.19M
Stockholders Equity Q2 2025 · Apr 30, 2023 $72.69M
Eps Diluted Q2 2025 · Oct 31, 2023 −$0.26
Eps Diluted Q2 2025 · Oct 31, 2023 −$0.85
Eps Basic Q2 2025 · Oct 31, 2023 −$0.26
Eps Basic Q2 2025 · Oct 31, 2023 −$0.85
Rd Expense Q2 2025 · Oct 31, 2023 $82.03K
Rd Expense Q2 2025 · Oct 31, 2023 $186.52K
Net Income Q2 2025 · Oct 31, 2023 $2.79M
Net Income Q2 2025 · Oct 31, 2023 −$393.4K
Net Income Q2 2025 · Jul 31, 2023 −$3.18M
Operating Income Q2 2025 · Oct 31, 2023 −$1.41M
Operating Income Q2 2025 · Oct 31, 2023 −$3.48M
Revenue Q2 2025 · Oct 31, 2023 $0
Revenue Q2 2025 · Oct 31, 2023 $0